Our clinically validated SpyVLP platform has produced a Phase II-ready CMV candidate (SPYVLP01) and a Phase I-ready EBV candidate (SPYVLP02). Our next-generation SpyVector adenoviral platform expands the breadth of what's possible — into oncology, tissue-targeted delivery and unadjuvanted T-cell vaccines.
SpyVLP is our flagship. HBsAg-based virus-like particles densely decorated with antigens via the irreversible SpyCatcher/SpyTag covalent bond — generating multivalent, high-density antigen displays that drive class-leading antibody responses. Two assets now stand at clinical inflection points.
VLPs already enjoy a proven regulatory path (cf. Gardasil-9). SpyVLP unlocks the breadth Gardasil never could — any antigen, any combination, any pathogen — with manufacturing simplicity and stability that makes global deployment feasible.
SpyVector is the future-facing potential of our toolkit — an adenoviral vector with SpyCatcher-modified hexons that can co-deliver covalently bound surface ligands and a programmable gene payload. We're investigating it across areas where conventional vectors fall short.
Display nanobodies, scFvs or peptides on hexon arms to route the vector to liver, lung, CNS or tumour — solving the off-target problem that plagues systemic gene therapy.
Tumour-selective promoters (hTERT, survivin, E2F) restrict replication to cancer tissue — combining tumour targeting, immune stimulation and selective oncolysis in one self-decorating vector.
Adenoviral innate sensing drives potent CD8+ responses without adjuvant — exploring applications in chronic infections (TB, HIV, HBV) and therapeutic cancer vaccines.
Encode shRNAs against oncogenes (KRAS, MYC, BCL-2) within the capsid — pairing tissue-targeted delivery with sustained silencing through capsid-shielded re-dosability.
Investigating delivery of CAR transgenes directly into T cells via hexon-displayed CD8 nanobodies — a potential breakthrough for the cost and access barriers of ex-vivo CAR-T.
Capsid decoration evades pre-existing anti-vector immunity — exploring repeat-dose adenoviral therapeutics where conventional vectors are precluded.
Our pipeline leads with two clinical-inflection assets on SpyVLP, with SpyVector advancing earlier-stage exploratory programs.
| Candidate | Platform | Target | Indication | Stage |
|---|---|---|---|---|
| SPYVLP01 | SpyVLP | CMV (Cytomegalovirus) | Congenital infection prevention | Phase II Ready |
| SPYVLP02 | SpyVLP | EBV (Epstein-Barr Virus) | IM prevention / MS risk reduction | Phase I Ready |
| SPYVEC-FLU | SpyVector | Influenza | Universal influenza vaccine | Preclinical |
| SPYVEC-Onc | SpyVector | Cancer Antigens | Therapeutic cancer vaccine | Discovery |
Beyond our clinical-stage programmes, the SpyCatcher/SpyTag scaffold supports a broad set of exploratory opportunities — from infectious-disease vaccines and biodefense candidates to veterinary applications and early therapeutic concepts. Tap any node to explore the disease context and platform fit.
World-class scientists, clinicians and business leaders from Oxford University, the Jenner Institute, and global pharma — driving the next generation of vaccine and therapeutic innovation.
Scientist working on protein engineering and antigen design for the SpyVLP and SpyVector platforms.
Co-founder and scientific leader of SpyBiotech. Sumi led the development of the SpyCatcher/SpyTag-based vaccine platform at the Jenner Institute, University of Oxford, and continues to lead the company’s research across SpyVLP and SpyVector programmes.
Research associate supporting platform R&D across antigen design, protein expression and in vitro characterisation.
Leads SpyBiotech’s corporate strategy and finance. Seasoned biotech executive with CXO experience across multiple emerging biotech and life-science companies, bringing deep operational and transactional expertise.
Senior scientist contributing to SpyVLP antigen optimisation, conjugation and in vivo characterisation.
Leads the SpyVector adenoviral platform programme, advancing hexon-modified vector technology for vaccines and tissue-targeted therapeutics.
Leads SpyBiotech's clinical strategy. Previously held senior clinical roles in major vaccine and biotech organisations, with deep experience guiding products from FIH through Phase III.
Manages SpyBiotech's financial operations, accounting, and reporting infrastructure.
Principal scientist driving SpyVLP and SpyVector R&D programmes — from antigen engineering through preclinical immunogenicity.
Senior scientist working on protein production, conjugation chemistry and platform characterisation.
Manages SpyBiotech's office operations, company administration, and team logistics.
Spun out from the University of Oxford with exclusive rights to apply SpyCatcher/SpyTag to vaccinology and therapeutics. Supported by deep-science investors building category-defining biotechs.
